Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.48 USD

8.48
1,027,632

-0.28 (-3.20%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $8.48 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

Bausch (BHC) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch (BHC) delivered earnings and revenue surprises of 13.86% and 7.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Ekta Bagri headshot

Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More

by Ekta Bagri

Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Bausch (BHC) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Bausch (BHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Best Value Stocks to Buy for February 7th

by Zacks Equity Research

MITSY, JSAIY and BHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 7, 2023.

UnitedHealth Group's (UNH) Brazil Unit Draws Buyout Interests

by Zacks Equity Research

UnitedHealth Group (UNH) expects to divest its troubled Brazil business, enhancing its overall results.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Are Medical Stocks Lagging Bausch Health (BHC) This Year?

by Zacks Equity Research

Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.

UnitedHealth Group's (UNH) Arm Launches OptumRx Weight Engage

by Zacks Equity Research

UnitedHealth Group (UNH) enhances Optum Rx's offerings with the launch of the Weight Engage program.

Implied Volatility Surging for On Bausch Health Companies (BHC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bausch Health Companies (BHC) stock based on the movements in the options market lately.

UnitedHealth (UNH) Unit Awarded a Medicaid Contract by AHCCCS

by Zacks Equity Research

UnitedHealth Group's (UNH) unit has been picked up by AHCCCS to serve members of the ALTCS EPD program, which will serve as a means to further expand the health insurer's statewide footprint.

Wall Street Analysts Think Bausch (BHC) Could Surge 30.14%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Bausch (BHC) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Humana (HUM) Extends CINQCARE's Home Care Model to MA Members

by Zacks Equity Research

Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.

Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.

Wall Street Analysts Believe Bausch (BHC) Could Rally 38.28%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 38.3% in Bausch (BHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Encompass Health (EHC) Opens Hospital to Boost Presence in Texas

by Zacks Equity Research

Encompass Health (EHC) opens an inpatient rehabilitation hospital in Prosper to address the diversified needs of the greater Dallas area residents. It marks EHC's 160th nationwide facility.

Has Aveanna Healthcare (AVAH) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Aveanna Healthcare (AVAH) and Bausch Health (BHC) have performed compared to their sector so far this year.

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

by Zacks Equity Research

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail

by Zacks Equity Research

UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.

Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.